EUVIMEDEUVIMED entdecken
Crossref

Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications

Yogi Puji Rachmawan, Witri Pratiwi, Bagus Andi Pramono, Erdiansyah Zulyadaini, Wella Karolina, Tuko Srimulyo, Meity Ardiana, Antonia Anna Lukito

Eurasian Journal of Medicine and Oncology · 16.11.2026 · 026310392

DOI: 10.36922/ejmo026310392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 16.11.2026. Verfasst von Yogi Puji Rachmawan und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Poor blood-pressure control and treatment resistance contribute to cardiovascular and kidney complications. Excess aldosterone offers a therapeutic target.

Objective

This narrative review evaluates the pharmacological profile, clinical efficacy, safety, and regulatory development of baxdrostat, an oral aldosterone synthase inhibitor designed to preserve cortisol production. Key findings: In BaxHTN, a phase 3 trial in uncontrolled or resistant hypertension, the placebo-adjusted decrease in seated systolic blood pressure at week 12 was 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg; Bax24, a phase 3 ambulatory blood-pressure trial in resistant hypertension, recorded a 14.0 mmHg placebo-adjusted decrease in 24-hour ambulatory systolic pressure with 2 mg. FigHTN, a phase 2 trial in chronic kidney disease, identified a preliminary albuminuria signal, but cardiorenal outcome studies have not yet been completed. The main recognised risks are hyperkalaemia and hyponatraemia, particularly when kidney function is impaired. The United States prescribing information states that safety and effectiveness of initiation at an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2 have not been established, and serum potassium, sodium, and eGFR require surveillance during initiation and dose adjustment. The United States Food and Drug Administration approved baxdrostat (Baxfendy) on May 15, 2026, as an add-on treatment for adults whose hypertension remains inadequately controlled. Concomitant use with a mineralocorticoid receptor antagonist has not been evaluated and should not presently be recommended.

Conclusion

Comparative and long-term outcome evidence is still required, while full efficacy and safety results of the completed phase 3 BaxAsia trial in Asian populations are awaited.

Zitieren

APA

Rachmawan, Y. P., Pratiwi, W., Pramono, B. A., Zulyadaini, E., Karolina, W., Srimulyo, T., Ardiana, M., & Lukito, A. A. (2026). Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications. Eurasian Journal of Medicine and Oncology, 0(0), 026310392. https://doi.org/10.36922/ejmo026310392

Vancouver

Rachmawan YP, Pratiwi W, Pramono BA, Zulyadaini E, Karolina W, Srimulyo T, et al. Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications. Eurasian Journal of Medicine and Oncology. 2026;0(0):026310392. doi:10.36922/ejmo026310392

BibTeX
@article{Rachmawan2026,
  author = {Rachmawan, Yogi Puji and Pratiwi, Witri and Pramono, Bagus Andi and Zulyadaini, Erdiansyah and Karolina, Wella and Srimulyo, Tuko and Ardiana, Meity and Lukito, Antonia Anna},
  title = {Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications},
  journal = {Eurasian Journal of Medicine and Oncology},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {026310392},
  doi = {10.36922/ejmo026310392}
}
Kostenlos starten →